Philadelphia FIGHT (FIGHT) was founded as the Community-Based Research Initiative on AIDS. Clinicians at FIGHT continue to be involved in a number of studies. Below are a list of clinical research trials at FIGHT.
The following clinical trials are ongoing at the Lax Center and currently enrolling patients:
A Phase 4, Randomized, Active-Controlled, Open-label Study to Evaluate the Safety and Tolerability of Switching to Once-Daily Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-dose Combination (FDC) Regimen in Virologically-suppressed Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Experiencing Rapid Weight Gain in an INI + TAF/FTC ARV Regimen [TMC114FD2HTX4004 – DEFINE]
Description: The purpose of this study is to evaluate potential changes in body weight and the safety and tolerability of an investigational mediation that has been approved for adults living with HIV-1. Call 215-525-8695 or email firstname.lastname@example.org for more information.
BEAT-HIV Delaney Collaboroatory
Are you interested in HIV cure-directed research? The Philadelphia based BEAT-HIV Delaney Collaboroatory is a group of more than 60 of the top HIV scientists from around the world working to advance the HIV cure research agenda. To get involved in an HIV cure-directed research trial, please call Linden Lalley-Chareczko, Research Program Director, at 215-525-8695.
The following clinical trials are ongoing at the Lax Center but are NOT enrolling new patients:
Open-label study to evaluate switching from a regimen of two NRTIs plus a third agent to a fixed dose combination of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed, HIV-1 infected, African American participants
Trial number: GS-US-380-4580
Description: A phase 3b, open-label study to evaluate switching from a regimen of two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus a third agent to a fixed dose combination (FDC) of bectegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed, HIV-1 infected, African American participants.
Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed Dose Combination Once Daily for Pre-Exposure Prophylaxis (PrEP)
Trial Number: GS-US-412-2055
Description: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women who have Sex with Men and are at Risk of HIV-1 Infection
Double-Blind Study to Evaluate Safety and Efficacy of GS-9883 versus Triumeq in HIV+, Treatment-Naïve Adults
Trial Number: GS-US-380-1489
Description: A Phase 3, randomized, double-blind study to evaluate the safety and efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 infected, antiretroviral treatment-naïve adults
Randomized, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1-infected adults who are virologically suppressed [TANGO]
Trial Number: 204862
Description: A phase 3, randomized study aiming to determine the efficacy, safety and tolerability of two approved medicines, dolutegravir (DTG) plus lamivudine (3TC) taken together, compared with subjects taking their current tenofovir alafenamide (TAF)-based regimen (TBR) for the treatment of HIV-1 infected adults in whom the HIV-1 virus is currently suppressed.
Switch Study to Evaluate D/C/F/TAF, Once-Daily versus Staying on a Boosted Protease Inhibitor Regimen
Trial Number: TMC114IFD3013
The Immunopathogenisis of HIV
Description: Sponsored by The Wistar Institute
The following clinical trials are ongoing at the YHEP Youth Health Center and currently enrolling patients:
|There are currently no trials enrolling at YHEP Health Center. Please check back soon!|
For more information on any of the clinical trials listed, please contact the Research Department at 215-525-8695.